USA - NASDAQ:VERO - US92332W3034 - Common Stock
The current stock price of VERO is 2.22 USD. In the past month the price decreased by -6.96%. In the past year, price decreased by -54.76%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.07 | 217.73B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.65 | 193.37B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.99 | 148.58B | ||
| SYK | STRYKER CORP | 28.91 | 142.00B | ||
| MDT | MEDTRONIC PLC | 16.67 | 118.23B | ||
| BDX | BECTON DICKINSON AND CO | 12.78 | 52.27B | ||
| IDXX | IDEXX LABORATORIES INC | 52.44 | 50.38B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.13 | 48.48B | ||
| RMD | RESMED INC | 26.8 | 37.35B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.55 | 35.22B | ||
| DXCM | DEXCOM INC | 40.51 | 27.01B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.65 | 26.77B |
Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. The company is headquartered in Toronto, Ontario and currently employs 292 full-time employees. The company went IPO on 2017-10-12. The firm develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services and reaches over 60 countries and nine direct markets. The Company’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Its treatments for hair loss are divided into non-surgical options and surgical procedures. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. Its systems are designed on flexible platforms that enable it to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family medicine and general practitioners and aesthetic medical spas.
VENUS CONCEPT INC
235 Yorkland Blvd Suite 900
TORONTO ONTARIO M2J 4Y8 CA
CEO: Domenic Serafino
Employees: 292
Phone: 18778488430
Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. The company is headquartered in Toronto, Ontario and currently employs 292 full-time employees. The company went IPO on 2017-10-12. The firm develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services and reaches over 60 countries and nine direct markets. The Company’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Its treatments for hair loss are divided into non-surgical options and surgical procedures. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. Its systems are designed on flexible platforms that enable it to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family medicine and general practitioners and aesthetic medical spas.
The current stock price of VERO is 2.22 USD. The price increased by 3.74% in the last trading session.
VERO does not pay a dividend.
VERO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
VERO stock is listed on the Nasdaq exchange.
VENUS CONCEPT INC (VERO) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
VENUS CONCEPT INC (VERO) has a market capitalization of 4.13M USD. This makes VERO a Nano Cap stock.
ChartMill assigns a fundamental rating of 1 / 10 to VERO. VERO may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months VERO reported a non-GAAP Earnings per Share(EPS) of -50.78. The EPS increased by 44.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.52% | ||
| ROE | -1776.32% | ||
| Debt/Equity | 6.82 |
For the next year, analysts expect an EPS growth of 76.72% and a revenue growth -9.41% for VERO